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ess: dnowak@zdn.am.loSummary Many anti-cancer drugs induce formation of lipid peroxidation products
that are toxic for lung cancer cells in vitro. We tested whether changes of serum
thiobarbituric acid reactive substances (TBARs) and Schiff’s bases (SB) are associated
with treatment efficacy in 37 small cell lung cancer (SCLC) patients. Subjects
received carboplatin (350mg/m2, i.v.—Day 1), vincristine (1.3mg/m2, i.v.—Day 1),
and etoposide (120mg/m2, oral dose—Days 1–4). Then 5 subsequent cycles were
repeated at 21-day intervals. Serum TBARs and SB were measured fluorimetrically
before and 6, 24 h after introduction of the 1st, 3rd and 6th cycles.
TBARs and SB levels rose 24 h after 1st chemotherapy in the whole group
(2.571.4 vs. 4.272.0 mmol/dl, Po0:001 and 26.3716.7 vs. 29.779.8 U430/ml,
Po0:01, respectively) and the highest increments were in 19 patients with complete
or partial response after 1st, 3rd and 6th cycles. In 9 subjects with progressive
disease occurring before the 2nd cycle (early progression) TBARs and SB decreased 6
and 24 h after the 1st cycle (4.371.2 vs. 3.471.4, Po0:05 vs. 2.770.9 mmol/dl,
Po0:05 and 50.2717.0 vs. 36.7713.2, Po0:05 vs. 36.5713.4 U430/ml, Po0:01,
respectively).
Patients survival correlated with the 1st cycle-induced TBARs (r ¼ 0:49, Po0:001)
and SB (r ¼ 0:56, Po0:002) increments. Subjects with negative SB and TBARs
increments (n ¼ 8) had shorter survival than those (n ¼ 29) with positive increments
in lipid peroxidation products (log rank test Po0:005). Monitoring of circulatory
TBARs and SB may be helpful for screening of SCLC patients with high risk of early
disease progression and chemotherapy failure.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Patients with lung cancer have increased concen-
tration of lipid peroxidation products in body fluids
that may result from systemic oxidative stress.
Plasma levels of malondialdehyde (MDA), a one of
the most important end-products of lipid peroxida-
tion were higher in lung cancer patients than in
healthy matched controls.1,2 Pleural exudates
obtained from these patients revealed higher
concentration of lipid peroxidation products and
decreased antioxidant defense than specimens
from subjects with non-malignant pulmonary dis-
eases.3 In addition, the content of end-products of
lipid peroxidation including MDA and spontaneous
H2O2 generation were higher in lung cancer tissue
than in matched-uninvolved lung parenchyma.4,5
Recently, MDA has been shown to induce cell
cycle arrest in a cell line derived from human large
cell lung carcinoma in vitro.6 Other lipid peroxida-
tion products generated from eicosapentaenoic
acid and docosahexaenoic acid were also able to
inhibit growth of lung adenocarcinoma cell cul-
tures.7 Moreover, strong immunoreactivity of pri-
mary lesions and metastatic lymph nodes for
glutathione peroxidase and superoxide dismutase,
enzymes that suppress lipid peroxidation, was
related to poor prognosis in patients with lung
adenocarcinoma.8 These suggest that elevated lipid
peroxidation may represent some kind of metabolic
adaptation favouring formation of products that
may inhibit lung cancer growth.
Many anticancer drugs are known to induce free
radical generation and cause peroxidative damage to
lipids and other biomolecules.2,9–12 The rise in
concentration of circulating lipid peroxidation pro-
ducts was observed in patients with different
carcinomas as a consequence of various chemother-
apy regimens.2,11 This could be responsible in part
for their neoplastic activity and also for the
development of side effects such as cardiomyopathy,
nephrotoxicity and lung fibrosis.9,13,14 To date, there
is no information available regarding association
between chemotherapy-induced alterations in serum
levels of lipid peroxidation products and treatment
efficacy in cancer patients. Therefore, in this study
we investigated changes of serum concentrations of
lipid peroxidation products, thiobarbituric acid
reactive substances (TBARs), and Schiff’s bases (SB)
after the 1st, 3rd and 6th courses of chemotherapy
regimen composed of carboplatin, vincristin and
etoposide in patients with small cell lung cancer
(SCLC) with respect to the treatment efficacy.
We describe herein the rise in serum TBARs and
SB concentrations after introduction of the 1st
course of chemotherapy that correlated with SCLCpatients survival. Non-responders with early occur-
rence of progressive disease and shortest survival
revealed the 1st cycle-induced decrease in circu-
latory lipid peroxidation products.Material and methods
Patients
Thirty-seven patients (mean age 56710 years, 12
women, 28 men) with previously untreated, histo-
logically or cytologically confirmed SCLC admitted
to District Chest Hospital Lagiewniki were recruited
for the study from March 1997 to August 1998. All
patients were required to have Karnofsky perfor-
mance status X60, adequate hematological
(white blood cell count44 103=ml, platelet
count4105=ml), renal (serum creatinine level
o1:5mg=dl) and hepatobiliary (serum bilirubin
level o1:5mg=dl) function. Pretreatment evalua-
tion consisted of a complete history and physical
examination, chest X-ray, bronchofibroscopy, com-
puterized tomographic scans of the chest, ultra-
sonography of abdomen, blood cell count and
serum chemistry analysis. Computerized tomo-
graphic scans of the central nervous system and
radionuclide bone scans were performed when
brain and bone metastases were suspected. Twenty
patients revealed limited stage (LD) and 17
extensive stage disease (ED) (Table 1). Sites of
metastases were liver—9 patients, bone—6 pa-
tients, and central nervous system—2 patients.
Blood cell count and serum chemistry analysis were
repeated prior to each cycle of chemotherapy.
Radiographic studies were reassessed following
every cycle or as indicated by clinical situation.
All subjects were smokers and did not change
smoking habits during the study. No patient had any
concomitant inflammatory disease during the study
period. The study had the approval of the Ethics
Committee of Medical University of Lodz, and
informed consent was obtained.
Treatment regimen and blood collection
The treatment regimen consisted of carboplatin
and etoposide (Bristol-Myers Squibb, Syracuse, NY)
and vincristine (Richter, Hungary). Carboplatin
(350mg/m2, i.v. infusion in 500ml of 0.9% saline
lasting 2 h), vincristine (1.3mg/m2, i.v. bolus, no
more than 2mg a day) and etoposide (120mg/m2,
single oral dose) were administered at the 1st day.
The administration of etoposide was continued for
the next 3 consecutive days. Following the initial
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Table 1 Characteristic of patients with small cell lung cancer (SCLC) and subgroups with limited (LD) and
extensive stage disease (ED).
Variable Whole SCLC group,
n ¼ 37
SCLC LD subgroup,
n ¼ 20
SCLC ED subgroup,
n ¼ 17
Age (years) 5679 5679 55710
Sex F/M 12/25 7/13 5/12
Body weight (kg) 70715 69712 70714
Karnofsky performance status 70710 70710 70710
Present cigarette consumption 3177 2879 3376
Cumulative cigarette consumption (pack
years)
56725 56730 55718
Haemoglobin (g/dl) 13.571.4 13.571.2 13.471.7
Platelets (cells  103/ml) 3147144 3527153 2767102
WBC (cells  103/ml) 8.772.3 8.172.3 9.472.3
Neutrophils (cells  103/ml) 6.072.2 5.271.8 6.972.2
Transferrin (mg/dl) 218761 236762 197753
Iron (mg/dl) 93730 89727 98733
Effect of chemotherapy in SCLC 1594-day cycle, 5 subsequent cycles were repeated at
21 day intervals. Additional treatment involved
antiemetic drugs, and oral corticosteroids if re-
quired. Blood specimens for determination of lipid
peroxidation products—TBARs, SB, were drawn just
before and 6, 24 h after introduction of the 1st, 3rd
and 6th courses of chemotherapy. Clotted blood
(30min incubation at 37 1C) was centrifuged and
obtained serum was stored at 80 1C for not longer
than 14 days.Response and toxicity criteria
Monthly evaluation of response to chemotherapy
involved clinical examination, assessment of the
chest X-ray, liver function tests, abdomen ultra-
sonography, computerized tomographic scans and
other imaging studies as clinically indicated.
Tumour response before the 3rd and 6th courses
of chemotherapy was evaluated by standard WHO
criteria. A complete response (CR) was defined as
resolution of all disease for a minimum of 4 weeks.
A partial response (PR) required a 50% or greater
decrease in the tumor size (the sum of the products
of measured lesions) for a minimum of 4 weeks
without the appearance of new lesions. Stable
disease (NC) was defined as a response less than a
partial response or progression less than that
defined as progressive disease, of at least four
week duration. Progressive disease (PD) was de-
scribed as a greater than 25% enlargement of an
indicator lesion or development of a new lesion.
Patients were classified as responders (complete
responseþ partial response) and non responders(stable diseaseþ progressive disease).The therapy
was discontinued in patients with progressive
disease. Patients who had a white blood cell
counto3 103=ml or plateletso104=ml on the day
of scheduled treatment had drug administration
delayed by 1 week (maximum 2 weeks) until the
counts rose above these levels. Since colony
stimulating factors may prime phagocytes to
enhanced ROS production with subsequent rise in
circulating lipid peroxidation products they were
not used during this study. From the same reasons
the radiation therapy was omitted in SCLC LD
patients.Lipid peroxidation products
Quantitative estimation of lipid peroxidation in-
cluded assays for TBARs and SB.15,16
TBARs—0.1ml of serum was mixed with 1ml of
0.05M sulphuric acid and 0.5ml of 1.23M trichlor-
oacetic acid and incubated for 5min at room
temperature. Then the sample was centrifuged
(1500g, 10min, 4 1C) and the pellet was suspended
in 2ml of distilled water acidified with HCl to pH ¼
2:5 and then 0.5ml 0.025M thiobarbituric acid
solution and 10 ml 0.01% butylated hydroxytoluene
was added. After vigorous shaking the sample was
boiled for 60min, mixed with 2.5ml of n-butanol
and again centrifuged (1500g, 10min, room tem-
perature). TBARs were measured fluorometrically
(excitation 515 nm, emission 546 nm) in the upper
(butanol) layer on a Perkin Elmer Luminescence
Spectrometer LS 50 B. Tetramethoxypropane
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and TBARs concentration was expressed in mmol/dl.
SB—70 ml of serum was mixed with 980 ml of
chloroform–methanol mixture (2:1, v/v), adjusted
to pH 2.3 with HCl and then vigorously shaken and
centrifuged (1500g, 10min, 20 1C). SB were deter-
mined fluorometrically (excitation 360 nm, emis-
sion 430 nm) in supernatant and results were
expressed in arbitrary units of fluorescence per
1ml of serum (U430/ml).
Other techniques
Blood cell count was performed with ABX MICROS
analyser (AVL, Montpellier France). Serum levels of
transferrin (nephelometric assay, Beckman Array
360 system) and iron were done by Diagnostic
Laboratory of Academic Teaching Hospital of
Medical University of Lodz.
Statistical analysis
Data are expressed as mean7SD (and median in the
case of patients survival). The effect of chemother-
apy cycles on serum TBARs and SB concentrations
was analyzed using Wilcoxon matched pairs tests
followed Friedman ANOVA test. The differences
between patients subgroups were computed with
Mann–Whitney U-test or Friedman ANOVA test.
Correlation coefficients were calculated by the
Spearman test. The log-rank test and the Kaplan–
Meier method were used for analysis of survival
from the treatment introduction. A P value o0:05
was considered significant.Results
Treatment results
Nineteen patients with SCLC (11 with LD and 8 with
ED) completed 6 courses of chemotherapy. They
had the complete or partial response (subgroup
of responders ) that was maintained at least up
to the end of treatment. Of them, two
patients were alive at the moment of study
completion (survival 41360 and 41764 days).
For the remaining 17 responders the survival
ranged from 125 to 869 days (median ¼ 311 days).
Eighteen patients (9 with LD and 9 with ED)
did not respond to the chemotherapy (non-respon-
ders, survival range 5–322 days, median 67 days).
In 9 patients (1 with LD and 8 with ED)
the progressive disease occurred before the
2nd chemotherapy cycle (early progression,survival from 5 to 65 days, median 22 days)
and in the other 9 patients (8 with LD and 1 with
ED) progressive disease was observed between
the 3rd and 6th courses (late progression, survival
69 days till 322 days, median 136 days). These
subjects were withdrawn from the chemotherapy
regimen, however, they received palliative
treatment (including radiotherapy and other antic-
ancer drugs) as needed. Also, patients who
completed 6 courses of chemotherapy received
further anticancer treatment according to indica-
tions. Fig. 1C shows individual patients survival
results ranging from 5 till 869 days (median ¼
151 days).Effect of the 1st chemotherapy course on
serum lipid peroxidation products
Figure 1(A and B) shows individual increments in
lipid peroxidation products after 24 h from intro-
duction of the 1st chemotherapy cycle. The TBARs
increment expressed as % of baseline (before the
1st chemotherapy cycle) value was negative in 8
patients and positive in 29 patients and ranged
from –62% to +737% (Fig. 1A). Serum SB increment
ranged from 56.1% to +151.3% and was negative in
9 subjects. There was a significant correlation
between TBARs and SB increments (r ¼ 0:63,
Po0:0001), as well as between baseline SB and
TBARs (r ¼ 0:53, Po0:001). In 28 patients, serum
TBARs and SB levels raised in response to che-
motherapy, in 8 subjects both variables decreased
and in one patient the increase in TBARs and
decrease in SB after treatment introduction was
observed (Fig. 1A and B). Baseline concentration of
TBARs and SB was higher in SCLC ED patients than in
SCLC LD subjects, 3.5270.31 mmol/dl vs.
1.7870.19 mmol/dl (Po0:0001) and 37.37
4.5 U430/ml vs. 17.071.5 U430/ml, (Po0:001), re-
spectively. The 1st cycle of chemotherapy
induced the significant rise in circulatory TBARs
and SB in the whole group of SCLC patients and
also in the subgroup of responders. The mean
TBARs and SB concentration increased by 1.61
and 1.13 times 24 h after the 1st chemotherapy
course introduction in the whole SCLC group
(Table 2). On the contrary, in non-responders no
rise and even significant decrease in end-products
of lipid peroxidation (TBARs at 6 and 24 h) was
observed. Prospective analysis revealed that the
1st cycle of chemotherapy did not increase serum
TBARs and SB levels only in SCLC ED non-responders
(Table 3).
The increase in circulatory end-products of
lipid peroxidation was observed in all remaining
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Figure 1 Individual serum TBARs (A) and Shiff’s bases (B) increments (expressed as % of baseline) after 24 h from
introduction of the 1st chemotherapy cycle and survival (C) of 37 small cell lung cancer (SCLC) patients. Patients
number on each graph represents the same subject. *, patient alive at the moment of study completion.
Effect of chemotherapy in SCLC 161subgroups with the highest rise in TBARs (2.78-fold)
and SB (1.62-fold) in SCLC LD responders.
The effect of the 1st chemotherapy course
on serum end-products of lipid peroxidation was
quite different in non-responders with early
and late progression. In non-responders with
the late progression, both TBARs and SB incr-
eased significantly 24 h after the 1st cycle intro-
duction while in subjects with early progr-
ession the decline was observed (Table 4). SCLC
patients with early progression had higher
baseline (before the 1st chemotherapy cycle)
TBARs and SB concentrations than those with the
late progression.Effect of consecutive chemotherapy cycles
on serum end-products of lipid peroxidationMonitoring of circulatory products of lipid
peroxidation in 19 SCLC responders showed
significant increase in TBARs (Po0:0001) and
SB (Po0:02) levels in blood samples taken
just before consecutive courses of chemo-
therapy (Fig. 2A and B). The baseline TBARs
and SB concentration before the 6th course
was 1.44 (Po0:01) and 1.21 times (Po0:01)
higher than that before the 1st one, respe-
ctively. On the other hand, the mean
ARTICLE IN PRESS
Table 3 Serum levels of TBARs and Schiff’s bases after introduction of the first cycle of chemotherapy in SCLC
responders and non-responders with limited (LD) or extensive stage disease (ED).
Group Variable Time after initiation of the first chemotherapy cycle (h)
0 6 24
SCLC LD responders, n ¼ 11 TBARs 1.570.5 2.171.5 4.372.0**
Schiff’s bases 14.974.1 16.976.5 24.175.7**
SCLC ED responders, n ¼ 8 TBARs 2.870.9## 3.771.9# 5.371.9*
Schiff’s bases 24.074.1## 26.978.3## 31.576.6*#
SCLC LD non-responders, n ¼ 9 TBARs 2.171.1 2.371.6 4.272.5*
Schiff’s bases 19.678.2 26.2713.3* 28.778.8*
SCLC ED non-responders, n ¼ 9 TBARs 4.271.3## 3.771.2 3.071.0*
Schiff’s bases 49.1718.2## 33.5714.2* 35.8713.6*
TBARs and Schiff’s bases are expressed in mmol/dl and U430/ml, respectively. Po0:05; Po0:01 vs. corresponding value just
before the chemotherapy cycle. #Po0:05; ##Po0:01 vs. corresponding value in SCLC patients with LD.
Table 4 Plasma TBARs and Schiff’s bases levels after introduction of the 1st cycle of chemotherapy in SCLC non-
responders that revealed progressive disease before the 2nd cycle (early progression) and between the 3rd and
6th cycles (late progression).
Group Variable Time after initiation of the first chemotherapy cycle (h)
0 6 24
SCLC early progression, n ¼ 9 TBARs 4.371.2 3.471.4 2.770.9*
Schiff’s bases 50.2717.0 36.7713.2* 36.5713.4**
SCLC late progression, n ¼ 9 TBARs 2.070.9## 2.5671.6 4.572.3**#
Schiff’s bases 18.575.8## 23.0711.4# 28.078.3**
TBARs and Schiff’s bases are expressed in mmol/dl and U430/ml, respectively. Po0:05; Po0:01 vs. corresponding value just
before the chemotherapy cycle. #Po0:05; ##Po0:001 vs. corresponding value in SCLC patients with early progression.
Table 2 Serum levels of TBARs and Schiff’s bases after introduction of the first chemotherapy cycle in the whole
group of SCLC patients and subgroup of responders and non-responders to chemotherapy.
Group Variable Time after initiation of the first chemotherapy cycle (h)
0 6 24
SCLC whole group, n ¼ 37 TBARs 2.571.4 2.971.5* 4.272.0***
Schiff’s bases 26.3716.7 25.4712.2 29.779.8**
SCLC responders, n ¼ 19 TBARs 2.171.4 2.871.5*** 4.772.0***
Schiff’s bases 18.776.1 21.178.7* 27.277.0***
SCLC non-responders, n ¼ 18 TBARs 3.171.6 3.071.5* 2.671.9***
Schiff’s bases 34.4720.5 29.9713.8 32.3711.7
TBARs and Schiff‘s bases are expressed in mmol/dl and U430/ml, respectively. Po0:05; Po0:01; Po0:001 vs. corresponding
value just before the chemotherapy cycle.
D. Nowak, M. Janczak162increments in serum concentrations of
TBARs and SB caused by chemotherapy were
highest for the 1st course and decreased
gradually (Po0:02 and 0.001) with treatmentduration (Fig. 2C and D). For instance, mean TBARs
increment was 1.68 times lower after the 6th
chemotherapy course than after the 1st one
(Po0:01).
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Figure 2 Mean concentrations of serum TBARs (A) and Schiff’s bases (B) measured in 19 SCLC responders just before the
1st, 3rd and 6th chemotherapy cycles. Mean increments in serum TBARs (C) and Schiff’s bases (D) measured 24 h after
introduction of appropriate chemotherapy cycle. *Po0:01 vs corresponding value at the 1st chemotherapy cycle.
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Figure 3 Kaplan–Meier cumulative curves of survival
ratio for SCLC subjects with negative (curve A, n ¼ 8) and
positive (curve B, n ¼ 29) serum TBARs increments 24 h
after introduction of the 1st chemotherapy cycle
composed from carboplatin, etoposide and vincristine.
Effect of chemotherapy in SCLC 163Patients survival and changes of lipid
peroxidation products after the 1st course of
chemotherapy
There was a positive correlation between the 1st
chemotherapy cycle-induced increment in circula-
tory TBARs and SB and patients survival; r ¼ 0:49,
Po0:001 and r ¼ 0:56, Po0:002, respectively.
There was also a difference between survival of
patients with negative (n ¼ 8) and positive (n ¼ 29)
TBARs increment (log-rank P value p0.005, Fig 3).
Similar difference was seen for patients with
negative (n ¼ 9) and positive (n ¼ 28) SB incre-ments (log-rank P value p0.002, graphic data not
shown) due to almost the same individual TBARs
and SB results distribution.Discussion
We found that chemotherapy composed of carbo-
platin, etoposide and vincristine increases the
serum levels of end-products of lipid peroxidation
in a majority of SCLC patients. This is compatible to
previous reports on enhanced generation of lipid
peroxidation products in response to cancer che-
motherapy.2,11 However, we describe for the first
time (to our knowledge) that changes of serum
levels of TBARs and SB are related to treatment
efficacy and patients survival. The highest rise in
serum TBARs and SB concentrations after the 1st
course introduction was seen in responders that
received all 6 cycles of chemotherapy. On the
contrary, the significant decrease in end products
of lipid peroxidation was observed in non-respon-
ders with progressive disease occurring before the
2nd chemotherapy cycle and shortest survival.
TBARs are low molecular weight compounds
formed via decomposition of certain primary and
secondary lipid peroxidation products.17 MDA is one
of the most important TBARs, however, it is formed
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D. Nowak, M. Janczak164not only during oxidative degradation of polyunsa-
turated fatty acids but is also generated as a side
product of eicosanoid formation and oxidative
damage to other non-lipid biomolecules such as
proteins, carbohydrates and nucleic acids. MDA can
react with primary amines to give few products
including fluorescent MDA:amine adduct called
conjugated SB.17 Positive correlations between
baseline SB and TBARs levels and between treat-
ment-induced increments in serum TBARs and SB in
SCLC patients are in accordance with these data.
All anticancer drugs used in our study have been
reported to generate free radicals and induce
oxidative stress with subsequent formation of lipid
peroxidation products.11,18–20 This clearly explains
the rise in circulatory TBARs and SB after che-
motherapy in the whole group of SCLC patients and
also in responders subgroup. However, non-respon-
ders especially those with early progression re-
vealed the 1st chemotherapy course-induced
decrease in both measured variables. Look and
Musch reported a marked chemotherapy-induced
increase in plasma TBARs levels in 10 of 12 patients
with different carcinomas (in the remaining 2
patients no decrease was noted) but they did not
analyze association between plasma TBARs and
response to the treatment.2 On the other hand,
cisplatin combination chemotherapy in patients
with lung cancer (group also involved SCLC
patients) caused the decrease in the whole blood
ability to produce reactive oxygen species upon
stimulation with phorbol esters. This was indepen-
dent of treatment efficacy, however, was mainly
related to the decrease in number of circulating
polymorphonuclear leucocytes.21 Contrary to this,
Sangeetha and coworkers reported increased plas-
ma TBARs concentration and superoxide anion and
H2O2 production by polymorphonuclear leukocytes
following cancer chemotherapy.11
Few hypotheses may by raised to explain
chemotherapy-induced decrease in SB and TBARs
in SCLC patients with early progressive disease.
Perhaps, (A) chemotherapy may favour accelerated
MDA conversion into SB resulting in circulatory
TBARs decrease. However, simultaneous decline in
serum SB levels argues against this explanation. (B)
Non-responders could have increased antioxidant
defence. This may be rather responsible for
inhibition of treatment-induced rise in serum TBARs
and SB but not for their decrease. In addition,
higher baseline SB and TBARs levels in non-
responders than in responders suggest enhanced
ROS formation and imbalance between oxidants
and antioxidants in SCLC patients with early
occurrence of progressive disease. (C) Chemother-
apy may enhance MDA (and other TBARs) catabo-lism by aldehyde dehydrogenases in liver17 with
secondary decrease in circulatory SB. Observation
that activity of aldehyde dehydrogenase can be
associated with tumor resistance to carboplatin and
other anticancer drugs22,23 supports this hypoth-
esis. In addition, 6 of 9 patients with negative
TBARs increments had metastases in liver at the
study entry. (D) MDA may be decomposed by excess
of oxidants.24,25 SCLC ED patients with early
occurrence of progressive disease are likely to
have enhanced systemic oxidative stress. Addi-
tional amounts of ROS generated by chemotherapy
could decompose MDA and be responsible for
decrease in measured circulatory TBARs and SB.
Two last hypotheses seem most likely but their
confirmation requires further studies.
Each consecutive chemotherapy cycle caused the
lower rise in circulatory TBARs and SB while
baseline levels of lipid peroxidation products rose
with treatment duration in responders subgroup.
Although plasma iron levels did not alter in these
patients, chemotherapy may induce appearance of
plasma nontransferrin-bound iron a potential pro-
oxidant and decrease the concentration of low
molecular weight antioxidants.26 On the other
hand, activity of cellular antioxidant enzymes
may increase secondarily to treatment-induced
oxidative stress27 and be responsible for lower
TBARs and SB increments after consecutive che-
motherapy courses.
Our results suggests that end-products of lipid
peroxidation may inhibit tumour growth in vivo.
This is consistent with the observation that anti-
tumour effect of degradable starch microspheres
was dependent on TBARs generation in carcinoma
tissues in rabbits.28 Essential fatty acids and
products of their metabolism are cytotoxic and
alter drug resistance of tumour cell cultures.29 In
addition, MDA at concentration 1mM induced the
cell cycle arrest of the lung cancer-derived cell line
in vitro.6 Although serum TBARs levels were many
times lower in SCLC patients it is possible that
TBARs concentrations in the close neighbourhood of
tumour may reach values similar to that used in
experiments in vitro. Low catalase activity30 and
increased hydrogen peroxide release from lung
cancer tissue4 may predispose to enhanced gen-
eration of lipid peroxidation products after che-
motherapy.
The ratio of LD to ED patients was similar in SCLC
responder and non-responder subgroups. However,
this was quite different in SCLC non-responders
with late progression and non-responders with early
progression subgroup (8/1 vs. 1/8). Non-responders
with early progression revealed a decrease in
circulatory TBARs and SB after introduction of
ARTICLE IN PRESS
Effect of chemotherapy in SCLC 165chemotherapy. It suggests that occurrence of ED at
the study entry predisposes to decrease in end-
products of lipid peroxidation in response to
chemotherapy. This may consist in increased base-
line ROS production and/or increased activity of
enzymes decomposing MDA and other TBARs.
No significant association between survival and
TBARs and SB changes was found in the SCLC
responders subgroup that revealed increase in end-
products of lipid peroxidation. Perhaps, the de-
crease in circulatory TBARs and SB has higher
significance and is important for early occurrence
of progressive disease and survival shortening. The
coexistence of treatment-induced TBARs and SB
decrease with other processes promoting tumour
growth cannot be excluded, however, it requires
further studies. In conclusion, we found that simple
monitoring of treatment (carboplatin, etoposide,
vincristine)-induced changes of end-products of
lipid peroxidation may by helpful for screening of
SCLC patients with high risk of early disease
progression and chemotherapy failure.Acknowledgements
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